D.S. Brar has been associated with the pharmaceutical industry for over three decades. He spent major part of his career (1977 – 2004) with Ranbaxy Laboratories Limited at various positions and rose to the level of President in 1993. He became the CEO and Managing Director of Ranbaxy in 1999. Mr. Brar stepped down from this position in 2004 to start his entrepreneurial journey and ventured with GVK Biosciences – a leading contract research and development organization providing discovery and development services to global life sciences companies. He also promoted Inogent Labs – an early development/ scale up company (now a wholly owned subsidiary of GVK Biosciences) and Davix Management Services – a pharmaceuticals focused consulting/advisory services company. Mr. Brar is the Chairman of Mphasis Limited and holds board positions in various Indian and international companies like Maruti Suzuki India Limited, Wockhardt Limited, Gland Pharma Limited and Mountain Trail Foods (India) Pvt. Ltd. He is also a special advisor to the Board of Directors of Adamas Pharmaceuticals Inc. and a member of the Advisory Board of the USA-India Chamber of Commerce (USAIC). From 2000–2007, Mr. Brar served as a Director of the Reserve Bank of India (RBI) and was also a member of the Inspection and Audit Sub-Committee of the Central Board of Directors of the RBI. Mr. Brar also served as a Senior Advisor to Kohlberg Kravis Roberts (KKR) – a global investment firm from 2011–2015.
Mr. Brar has also been actively involved with some of the premier research institutions, educational institutions and industry associations in India.
G V Sanjay Reddy is the Vice Chairman of GVK PIL ( www.gvk.com ), a conglomerate with interests in Energy, Airports, Transportation, Resources, Real Estate, Hospitality and Life Sciences.
He was instrumental in making GVK the largest private airport operator in India, by owning, developing and operating the Mumbai and Bengaluru airports, which handles over 50 million passengers per year. He is involved with GVK EMRI – 108 Emergency Services (www.emri.in), which is the world’s largest ambulance service offered free of cost to over 800 million people across India and having saved more than one million lives till date. He holds a Bachelor’s Degree in Industrial Engineering from Purdue University, Indiana and an MBA from University of Michigan.
Sahajbir Singh Brar (Sej) is a Partner in L.E.K. Consulting’s Global Healthcare practice. He holds a Master of Business Administration from Harvard Business School from where he graduated with distinction honors and a Bachelor of Arts (cum laude honors) in Economics and International Relations from Tufts University.
He has over fifteen years of experience advising bio pharma companies and investors in healthcare on issues relating to corporate strategy, business development / M&A, commercial excellence and operational improvement.
Prior to L.E.K., Sahajbir worked in strategy consulting at Deloitte and at the Monitor Group. His healthcare industry experience spans specialty bio pharma, pharma services, generics and consumer healthcare / OTC. He has a particular focus on advising innovative pharma companies and leading institutional investors on strategic issues relating to growth, investment and organizational performance.
Indira Krishna Reddy is the Managing Director of Taj GVK Hotels & Resorts Limited. She is also the Director on the boards of various companies of the GVK Group.
G V Keshav Reddy holds an MBA from MIT Sloan School of Management and a Certificate in Innovation and Entrepreneurship from the MIT Martin Trust Center for Entrepreneurship. Keshav earned a Bachelor’s degree in Industrial Engineering and Operations Research from University of Michigan – Ann Arbor and a Certificate in Entrepreneurship from the College of Engineering.
Starting his career in 2014 in the Airports business, Keshav worked in different areas of corporate finance and M&A working on projects of equity fund raising and debt. Keshav was responsible for non-aeronautical revenue management overseeing USD $150M in revenues from various categories including duty-free, retail, F&B, advertising, and lounges.
In the past, Keshav worked as an intern at McKinsey & Company, Planning Commission (Government of India), Thiess Mining, and 3i private equity. Keshav is part of the INK Fellowship, Milken Institute Young Leaders Circle and World Economic Forum Young Shapers.
Robert R. Ruffolo is a distinguished scientist with a number of global recognitions for his executive leadership in the Pharmaceutical industry. He was appointed to the Board of Directors of GVK BIO in April 2019.
Dr. Ruffolo holds a B.S. degree in Pharmacy, and a Ph.D. degree in Pharmacology, both from The Ohio State University.
He served as the President of R&D and Senior Vice President of Wyeth Pharmaceuticals (now, Pfizer) from 2002 to 2008. Prior to Wyeth, Dr. Ruffolo was the Senior Vice President in R&D at SmithKline Beecham Pharmaceuticals (now GSK) for 17 years. He played a significant role in the discovery and development of a number of marketed products, including Carvedilol, Ropinirole, Dobutamine and Eprosartan, among others. He has been recognized with several prestigious awards, including the Discoverer’s Award in 2008 for his pioneering work on the discovery of Carvedilol for the treatment of congestive heart failure. Dr.Ruffolo currently serves as a Director at Sigilon Therapeutics, Elucida Oncology, Sapience Therapeutics and Aridis Pharmaceuticals. He is also the President of Ruffolo Consulting LLC, a position he has held since 2008.
Gerhard Mayr is on the Board of Directors of GVK BIO since July 2009. He holds a Master’s degree in Chemical Engineering from the Swiss Federal Institute of Technology, Zurich, Switzerland and a Master of Business Administration degree from Stanford University.
In March 2004, he retired as Executive Vice President of pharmaceutical operations at Eli Lilly and Company after 32 years of service. He was responsible for global pharmaceutical operations, sales and marketing worldwide at Eli Lilly – a leading innovation driven corporation. Gerhard is a member of the Board of Union Chimique Belge (UCB) since 2005 and is serving as the Chairman there since 2012. He is also a member of the Board of Almirall SA since 2012, member of the board of the Vienna Science, Research and Technology Foundation since 2002 and a member of the board of Project Hope, USA since 2002. He is a member of the circle of patrons of INSEAD Business School since 2000.
Sanjiv Dwarkanath Kaul joined the Board of GVK Biosciences in February 2016 representing ChrysCapital. Kaul is a Partner at Chryscapital and leads the healthcare and consumer sectors. Kaul is a pharmacy graduate, who has received an AMP from Harvard Business School and MBA from Indian Institute of Management, Ahmedabad.
He has 27 years of management experience in the pharmaceutical industry prior to joining ChrysCapital in July 2004, of which the last two decades were with Ranbaxy. He held several key leadership positions including Country Head for China, Regional Director for India and the Middle East at Ranbaxy. He also served as the Vice President and Head of Corporate Affairs for Ranbaxy.
Manni is the Director and Chief Executive Officer of GVK BIO. He joined GVK BIO in 2007 as President and has steered the company’s direction towards growth, to be one of Asia’s leading life sciences solutions organization.
Manni holds a Master of Science Degree in Computer Science from Arizona State University and a BE in Computer Engineering from Bombay University. He completed all his Ph.D. requirements and joined Intel prior to completing his dissertation.
Manni is also a Director and Chairperson on the Board of Aragen Bioscience, Inc., a fully owned subsidiary of GVK BIO, based in Morgan Hill, California, U.S.A. Prior to joining GVK BIO, Manni was in the IT industry, where he spent 16 years with Intel, holding various leadership positions in U.S.A and Asia. He served as the head of Intel India, the CIO of Intel for Asia and was responsible for the software in Intel’s Wi-Fi product line - Centrino.